ABSTRACT: Objectives: Vancomycin remains a first-line treatment for methicillin-resistant Staphylococcus aureus (MRSA)-mediated acute pulmonary exacerbations (APEs) in adult cystic fibrosis (CF) patients; however, optimal alternatives remain poorly defined.The aim of this study was to determine the safety and efficacy of ceftaroline for MRSA-mediated craggy range sauvignon blanc 2022 APEs of CF in adults.Methods: We conducted a retrospective, observational cohort study comparing ceftaroline with vancomycin for the treatment of MRSA-mediated APEs in adult CF patients.The primary endpoint was the return to at least 90% of baseline lung function measured by discharge FEV1% predicted in comparison with baseline FEV1% predicted.
Results: A total of 55 patients were included in the analysis (22 receiving ceftaroline and 33 receiving vancomycin).Of here the patients included in the analysis, 13 patients (59%) in the ceftaroline group and 24 patients (73%) in the vancomycin group met the primary outcome (P = 0.38).FEV1 measurements at baseline, admission and discharge were not different between treatments.
Secondary outcomes including 30-day re-admission rate, 30-day mortality, treatment duration and adverse events (neutropenia, Clostridioides difficile infection and acute kidney injury) were similar between groups.Conclusion: Our small cohort study supports ceftaroline as an alternative treatment option for MRSA-mediated APE of CF in adults.